Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly plans to buy privately held ⁠Merida Biosciences for ‌up to $2.88 billion in cash.

Published by
CNBC
Published
Length
107 words · 1 min
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly ​said on Monday it would buy privately held Merida Biosciences for up to $2.88 billion in cash, as it seeks to expand its pipeline of potential treatments for immunity-related and allergic diseases.

Lilly has been on an acquisition spree, boosted by the booming demand for its obesity drugs. Its deal spending in 2026 has outpaced that in the prior years.

Merida is developing medicines to selectively target antibodies that cause a range of immunity-related conditions.

Its lead drug candidate, MER511, is in the early stage of development for autoimmune disorders such as Graves' disease and thyroid eye disease.

This story is developing. Please check back for updates.

Where this came from

This story was first published by CNBC on 31 Aug 2026. HUE Legacy Ventures did not write it.

Carried in full with attribution and a link to the original. Rights remain with the publisher, who may request removal at any time.

Read it at cnbc.com →